Catalysts for Samsung Bioepis Co Ltd
65 tracked
Feb 28, 2025
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
Feb 13, 2025
approval
DENOSUMAB-DSSB — FDA approval
denosumab biosimilar
→
Jan 28, 2025
approval
EPYSQLI (ECULIZUMAB-AAGH) — FDA approval
EPYSQLI
→
Jan 21, 2025
approval
EPYSQLI (ECULIZUMAB-AAGH) — FDA approval
EPYSQLI
→
Dec 20, 2024
approval
PYZCHIVA (USTEKINUMAB-TTWE) — FDA approval
PYZCHIVA
→
Dec 20, 2024
approval
PYZCHIVA (USTEKINUMAB-TTWE) — FDA approval
PYZCHIVA
→
Dec 20, 2024
approval
PYZCHIVA (USTEKINUMAB-TTWE) — FDA approval
PYZCHIVA
→
Nov 15, 2024
approval
EPYSQLI (ECULIZUMAB-AAGH) — FDA approval
EPYSQLI
→
Jul 19, 2024
approval
EPYSQLI (ECULIZUMAB-AAGH) — FDA approval
EPYSQLI
→
Jun 28, 2024
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Jun 28, 2024
approval
PYZCHIVA (USTEKINUMAB-TTWE) — FDA approval
PYZCHIVA
→
Jun 28, 2024
approval
PYZCHIVA (USTEKINUMAB-TTWE) — FDA approval
PYZCHIVA
→
May 20, 2024
approval
OPUVIZ (AFLIBERCEPT-YSZY) — FDA approval
OPUVIZ
→
May 3, 2024
approval
ETICOVO (ETANERCEPT-YKRO) — FDA approval
ETICOVO
→
May 3, 2024
approval
ETICOVO (ETANERCEPT-YKRO) — FDA approval
ETICOVO
→
Dec 26, 2023
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Oct 3, 2023
approval
BYOOVIZ (RANIBIZUMAB-NUNA) — FDA approval
BYOOVIZ
→
Jul 11, 2023
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Jun 26, 2023
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Jun 16, 2023
approval
BYOOVIZ (RANIBIZUMAB-NUNA) — FDA approval
BYOOVIZ
→
Apr 26, 2023
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Dec 23, 2022
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Aug 15, 2022
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Aug 15, 2022
approval
BYOOVIZ (RANIBIZUMAB-NUNA) — FDA approval
BYOOVIZ
→
Jun 17, 2022
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→
Jun 9, 2022
approval
BYOOVIZ (RANIBIZUMAB-NUNA) — FDA approval
BYOOVIZ
→
Jan 27, 2022
approval
RENFLEXIS (INFLIXIMAB-ABDA) — FDA approval
infliximab biosimilar
→
Sep 17, 2021
approval
BYOOVIZ (RANIBIZUMAB-NUNA) — FDA approval
BYOOVIZ
→
Mar 19, 2020
approval
ONTRUZANT (TRASTUZUMAB-DTTB) — FDA approval
ONTRUZANT
→
Jul 23, 2019
approval
HADLIMA (ADALIMUMAB-BWWD) — FDA approval
HADLIMA
→